{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:45:44Z","timestamp":1792784744921,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Health and Medical Research Council of Australia","award":["APP1158283"],"award-info":[{"award-number":["APP1158283"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Queensland State Government","id":[{"id":"https:\/\/ror.org\/035dsh769","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.addr.2019.11.002","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T11:48:29Z","timestamp":1573040909000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"special_numbering":"C","title":["Topical treatments for skin cancer"],"prefix":"10.1016","volume":"153","author":[{"given":"Jason K.","family":"Cullen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta L.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen M.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2019.11.002_bb0005","series-title":"Sunlight, Vitamin D and Skin Cancer","first-page":"120","article-title":"Epidemiology of skin cancer","author":"Leiter","year":"2014"},{"key":"10.1016\/j.addr.2019.11.002_bb0010","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.addr.2019.11.002_bb0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amepre.2014.08.036","article-title":"Prevalence and costs of skin cancer treatment in the U.S., 2002\u20132006 and 2007\u20132011","volume":"48","author":"Guy","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.addr.2019.11.002_bb0020","series-title":"Lyon, France: International Agency for Research on Cancer","author":"Global Cancer Observatory: Cancer Today","year":"2018"},{"key":"10.1016\/j.addr.2019.11.002_bb0025","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2019.11.002_bb0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.addr.2019.11.002_bb0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5694\/mja17.00284","article-title":"The incidence and multiplicity rates of keratinocyte cancers in Australia","volume":"207","author":"Pandeya","year":"2017","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.addr.2019.11.002_bb0040","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng.3525","article-title":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","volume":"48","author":"Bonilla","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2019.11.002_bb0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012","volume":"68","author":"Karia","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Pract. Concept."},{"key":"10.1016\/j.addr.2019.11.002_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-016-0165-y","article-title":"Skin Cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"10.1016\/j.addr.2019.11.002_bb0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.15324","article-title":"Cutaneous squamous cell carcinoma: an epidemiological review","volume":"177","author":"Green","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ced.12713","article-title":"Histopathological study of perilesional skin in patients diagnosed with nonmelanoma skin cancer","volume":"41","author":"Apalla","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ijd.12553","article-title":"Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends","volume":"54","author":"Kallini","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0075","first-page":"1099","article-title":"The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma","volume":"33","author":"Fuchs","year":"2007","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.addr.2019.11.002_bb0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjd.12420","article-title":"The natural history of actinic keratosis: a systematic review","volume":"169","author":"Werner","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0085","first-page":"1002","article-title":"Nonmelanoma skin cancer \u2013 from actinic keratosis to cutaneous squamous cell carcinoma","volume":"16","author":"Schmitz","year":"2018","journal-title":"JDDG"},{"key":"10.1016\/j.addr.2019.11.002_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5694\/j.1326-5377.2006.tb00086.x","article-title":"Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985","volume":"184","author":"Staples","year":"2006","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.addr.2019.11.002_bb0095","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-4632.2010.04474.x","article-title":"Ultraviolet radiation and skin cancer","volume":"49","author":"Narayanan","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1440-0960.2006.00218.x","article-title":"Defining patients with high-risk cutaneous squamous cell carcinoma","volume":"47","author":"Veness","year":"2006","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0105","series-title":"Cancer Facts and Figures 2019","author":"American Cancer Society","year":"2019"},{"key":"10.1016\/j.addr.2019.11.002_bb0110","series-title":"Melanoma of the Skin","author":"SEER Cancer Stat Facts","year":"2019"},{"key":"10.1016\/j.addr.2019.11.002_bb0115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0120","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaad.2011.04.031","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"65","author":"Bichakjian","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0125","doi-asserted-by":"crossref","first-page":"212281","DOI":"10.7573\/dic.212281","article-title":"Diagnosis and management of lentigo maligna: a review","volume":"4","author":"Kasprzak","year":"2015","journal-title":"Drug. Context"},{"key":"10.1016\/j.addr.2019.11.002_bb0130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1440-1681.1998.tb02339.x","article-title":"5-fluorouracil: a pharmacological paradigm in the use of cytotoxics","volume":"25","author":"Thomas","year":"1998","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.addr.2019.11.002_bb0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/np020034f","article-title":"5-fluorouracil derivatives from the sponge Phakellia fusca","volume":"66","author":"Xu","year":"2003","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.addr.2019.11.002_bb0140","first-page":"433","article-title":"5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction","volume":"33","author":"Gross","year":"2007","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.addr.2019.11.002_bb0145","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archdermatol.2009.291","article-title":"Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review","volume":"145","author":"Love","year":"2009","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","article-title":"Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial","volume":"14","author":"Arits","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2019.11.002_bb0155","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jid.2017.09.033","article-title":"Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma","volume":"138","author":"Jansen","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0160","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","article-title":"Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial","volume":"151","author":"Pomerantz","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0165","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0149-2918(02)80012-1","article-title":"Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis","volume":"24","author":"Loven","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2019.11.002_bb0170","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1203475416659259","article-title":"Low-dose 0.5% 5-fluorouracil\/10% salicylic acid topical solution in the treatment of actinic Keratoses","volume":"20","author":"Herranz","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.addr.2019.11.002_bb0175","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","article-title":"Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results","volume":"165","author":"Stockfleth","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13555-016-0161-2","article-title":"Efficacy and safety of 5-fluorouracil 0.5%\/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial","volume":"7","author":"Stockfleth","year":"2017","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.addr.2019.11.002_bb0185","first-page":"340","volume":"6","author":"Leroux","year":"1830","journal-title":"Journal de chimie m\u00e9dicale, de pharmacie et de toxicologie"},{"key":"10.1016\/j.addr.2019.11.002_bb0190","first-page":"405","article-title":"Ueber das Rigatellische Fiebermittel und \u00fcber eine in der Weidenrinde entdeckte alcaloidische Substanz (On Rigatelli's antipyretic and on an alkaloid substance discovered in willow bark)","volume":"29","author":"Buchner","year":"1828","journal-title":"Repertorium f\u00fcr die Pharmacie"},{"key":"10.1016\/j.addr.2019.11.002_bb0195","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archderm.142.6.729","article-title":"Comparison of topical methyl Aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial","volume":"142","author":"Morton","year":"2006","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2133.2003.05033.x","article-title":"Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen\u2019s disease","volume":"148","author":"Salim","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0205","series-title":"Case of the Month June","article-title":"Presurgical, neoadjuvant treatment of Bowens\u2019 disease with 0.5% 5-fluorouracil in 10% salicylic acid European Association of Dermato Oncology","author":"Giuffrida","year":"2017"},{"key":"10.1016\/j.addr.2019.11.002_bb0210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1524-4725.1980.tb00900.x","article-title":"Treatment of lentigo maligna and lentigo maligna melanoma","volume":"6","author":"Coleman","year":"1980","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"10.1016\/j.addr.2019.11.002_bb0215","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/1097-0142(197503)35:3<721::AID-CNCR2820350327>3.0.CO;2-#","article-title":"Topical chemotherapy of lentigo maligna with 5-fluorouracil","volume":"35","author":"Litwin","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2019.11.002_bb0220","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-011-9717-2","article-title":"Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil","volume":"30","author":"Florin","year":"2012","journal-title":"Investig. New Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2019.11.002_bb0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Schon","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8369690","article-title":"Mediators of inflammation in topical therapy of skin cancers","volume":"2019","author":"Voiculescu","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2019.11.002_bb0235","first-page":"708","article-title":"Imiquimod as an antiangiogenic agent","volume":"4","author":"Li","year":"2005","journal-title":"J. Drugs. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.det.2004.08.007","article-title":"Imiquimod for the treatment of skin cancer","volume":"23","author":"Burns","year":"2005","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.addr.2019.11.002_bb0245","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1440-0960.2006.00265.x","article-title":"Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study","volume":"47","author":"Vun","year":"2006","journal-title":"Australas J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0250","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0255","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1470-2045(13)70530-8","article-title":"g. Surgery versus Imiquimod for nodular superficial basal cell carcinoma study, surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial","volume":"15","author":"Bath-Hextall","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2019.11.002_bb0260","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jid.2016.10.019","article-title":"Imiquimod for, G. superficial basal cell carcinoma Study, Surgery Versus 5% Imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial","volume":"137","author":"Williams","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0265","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1067\/mjd.2002.123492","article-title":"Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis","volume":"47","author":"Persaud","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0275","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% Imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0280","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00042728-200506000-00008","article-title":"Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream","volume":"31","author":"Lee","year":"2005","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.addr.2019.11.002_bb0285","first-page":"166","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies","volume":"13","author":"Swanson","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0290","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/0253-7613.161249","article-title":"Imiquimod - its role in the treatment of cutaneous malignancies","volume":"47","author":"Bubna","year":"2015","journal-title":"Indian J. Pharm."},{"key":"10.1016\/j.addr.2019.11.002_bb0295","first-page":"165","article-title":"Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream","volume":"10","author":"Hanke","year":"2011","journal-title":"J. Drugs Dermatol."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2019.11.002_bb0300","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0305","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1524-4725.2012.02480.x","article-title":"Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study","volume":"38","author":"Ondo","year":"2012","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.addr.2019.11.002_bb0310","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1684\/ejd.2012.1771","article-title":"Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients","volume":"22","author":"Tiodorovic-Zivkovic","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0315","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/0956462414553615","article-title":"Successful treatment of genital Bowen\u2019s disease with imiquimod 5% cream","volume":"26","author":"Kishi","year":"2015","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.addr.2019.11.002_bb0320","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2229-5178.142570","article-title":"Bowen\u2019s disease: a favorable response to imiquimod","volume":"5","author":"Barad","year":"2014","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.addr.2019.11.002_bb0325","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12431","article-title":"Squamous cell carcinoma of the penis successfully treated with imiquimod 5% cream in a porphyria cutanea tarda patient","volume":"30","author":"Fernandez-Crehuet","year":"2017","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.addr.2019.11.002_bb0330","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/1346-8138.13528","article-title":"Topical 5% imiquimod eliminated human papillomavirus 16-associated Bowen\u2019s disease","volume":"44","author":"Nishimura","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0335","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.jcjo.2018.03.010","article-title":"Treatment of squamous cell carcinoma of the eyelid with imiquimod 5% cream","volume":"54","author":"Singh","year":"2019","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.addr.2019.11.002_bb0340","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhsa.2010.02.027","article-title":"Bone invasion by squamous cell carcinoma in situ (Bowen's disease) of the finger during treatment with imiquimod 5% cream: case report","volume":"35","author":"Gong","year":"2010","journal-title":"J. Hand. Surg. [Am.]"},{"key":"10.1016\/j.addr.2019.11.002_bb0345","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1046\/j.1365-2133.2000.03787.x","article-title":"Imiquimod: a novel treatment for lentigo maligna","volume":"143","author":"Ahmed","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0350","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2340\/00015555-1861","article-title":"Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate","volume":"95","author":"Kirtschig","year":"2015","journal-title":"Acta Derm. Venereol."},{"issue":"Suppl. 66","key":"10.1016\/j.addr.2019.11.002_bb0355","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.0366-077X.2003.05637.x","article-title":"Treatment of lentigo maligna with topical imiquimod","volume":"149","author":"Naylor","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0360","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/archderm.141.4.510","article-title":"Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod","volume":"141","author":"Wolf","year":"2005","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0365","first-page":"551","article-title":"Observational study of topical imiquimod immunotherapy in the treatment of difficult lentigo maligna","volume":"2","author":"Craythorne","year":"2008","journal-title":"Clin. Med. Oncol."},{"key":"10.1016\/j.addr.2019.11.002_bb0370","doi-asserted-by":"crossref","DOI":"10.1097\/GOX.0000000000000041","article-title":"Successful treatment of lower eyelid melanoma in situ","volume":"2","author":"Gassman","year":"2014","journal-title":"Plast. Reconstr. Surg. Glob. Open."},{"key":"10.1016\/j.addr.2019.11.002_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000496052","article-title":"Malignant melanoma treated with topical Imiquimod: a bespoke treatment that spared the amputation","volume":"11","author":"Verga","year":"2019","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0380","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/cam4.402","article-title":"Using topical imiquimod for the management of positive in situ margins after melanoma resection","volume":"4","author":"Pandit","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2019.11.002_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-203826","article-title":"Use of imiquimod for residual acral melanoma","volume":"2014","author":"Sue","year":"2014","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.addr.2019.11.002_bb0390","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/CJI.0b013e31827457bd","article-title":"Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma","volume":"35","author":"Kidner","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.addr.2019.11.002_bb0395","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00262-016-1880-z","article-title":"Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases","volume":"65","author":"Mauldin","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2019.11.002_bb0400","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/267535","article-title":"Melanoma arising after imiquimod use","volume":"2014","author":"Paul","year":"2014","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.addr.2019.11.002_bb0405","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1751-1097.1992.tb04222.x","article-title":"How does photodynamic therapy work?","volume":"55","author":"Henderson","year":"1992","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.addr.2019.11.002_bb0410","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cancers8100090","article-title":"Photodynamic therapy for non-melanoma skin cancers","volume":"8","author":"Cohen","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2019.11.002_bb0415","first-page":"50","article-title":"Photodynamic therapy in the treatment of basal cell carcinoma","volume":"6","author":"Matei","year":"2013","journal-title":"J. Med. Life"},{"key":"10.1016\/j.addr.2019.11.002_bb0420","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.biotechadv.2012.04.003","article-title":"Recent advances in microbial production of delta-aminolevulinic acid and vitamin B12","volume":"30","author":"Kang","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2019.11.002_bb0425","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1038\/srep08584","article-title":"Optimization of the heme biosynthesis pathway for the production of 5-aminolevulinic acid in Escherichia coli","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2019.11.002_bb0430","first-page":"1481","article-title":"Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture","volume":"57","author":"Gaullier","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2019.11.002_bb0435","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2010.03877.x","article-title":"Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response","volume":"25","author":"Fantini","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.addr.2019.11.002_bb0440","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1468-3083.2012.04619.x","article-title":"Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma","volume":"27","author":"Cosgarea","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.addr.2019.11.002_bb0445","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1468-3083.2008.02803.x","article-title":"A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up","volume":"22","author":"Szeimies","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.addr.2019.11.002_bb0450","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archderm.143.9.1131","article-title":"Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma","volume":"143","author":"Rhodes","year":"2007","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0455","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1751-1097.2007.00260.x","article-title":"Photodynamic therapy of nonmelanoma skin Cancer with topical Hypericum perforatum extract\u2014a pilot Study","volume":"84","author":"Kacerovsk\u00e1","year":"2008","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.addr.2019.11.002_bb0460","series-title":"Levulan\u00ae Kerastick\u00ae Package Insert","author":"I.W. DUSA Pharamceuticuals, MA, USA","year":"2010"},{"key":"10.1016\/j.addr.2019.11.002_bb0465","series-title":"Ameluz\u00ae Product Information","author":"B.A.L. Germany","year":"2018"},{"key":"10.1016\/j.addr.2019.11.002_bb0470","series-title":"Thornhill","author":"O. Galderma Laboratories Inc","year":"2009"},{"key":"10.1016\/j.addr.2019.11.002_bb0475","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jdv.13788","article-title":"Pain management in photodynamic therapy using a nitrous oxide\/oxygen mixture: a prospective, within-patient, controlled clinical trial","volume":"31","author":"Fink","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.addr.2019.11.002_bb0480","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archderm.140.1.41","article-title":"Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials","volume":"140","author":"Piacquadio","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0485","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1365-2133.2006.07520.x","article-title":"Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up","volume":"155","author":"Tschen","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0490","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1067\/mjd.2003.49","article-title":"Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial","volume":"48","author":"Pariser","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0495","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40257-018-0360-y","article-title":"Daylight photodynamic therapy for actinic Keratoses","volume":"19","author":"Morton","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0500","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jdv.13558","article-title":"Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers","volume":"30","author":"Tarstedt","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.addr.2019.11.002_bb0505","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1590\/abd1806-4841.20154080","article-title":"Long-term recurrence of nonmelanoma skin cancer after topical methylaminolevulinate photodynamic therapy in a dermato-oncology department","volume":"90","author":"Cabete","year":"2015","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0510","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.0906-6705.2005.00303.x","article-title":"5-aminolaevulinic acid photodynamic therapy in a transgenic mouse model of skin melanoma","volume":"14","author":"Cordoba","year":"2005","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0515","article-title":"Robust photodynamic therapy using 5-ALA-incorporated Nanocomplexes cures metastatic melanoma through priming of CD4(+)CD8(+) double positive T cells","volume":"6","author":"Li","year":"2019","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.addr.2019.11.002_bb0520","first-page":"633","article-title":"The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers","volume":"164","author":"Ramsay","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1440-0960.2010.00626.x","article-title":"PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial","volume":"51","author":"Siller","year":"2010","journal-title":"Australas J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0530","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/dth.12399","article-title":"Successfully treated superficial basal cell carcinomas with ingenol mebutate 0.05% gel: report of twenty cases","volume":"29","author":"Izzi","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.addr.2019.11.002_bb0535","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/CCID.S109531","article-title":"Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%","volume":"9","author":"Bettencourt","year":"2016","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0540","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5826\/dpc.0802a12","article-title":"Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel","volume":"8","author":"Iannazzone","year":"2018","journal-title":"Dermatol. Pract. Concept."},{"key":"10.1016\/j.addr.2019.11.002_bb0545","first-page":"1","article-title":"Ingenol mebutate: an introduction","volume":"17","author":"Fallen","year":"2012","journal-title":"Skin Ther. Lett."},{"key":"10.1016\/j.addr.2019.11.002_bb0550","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/dth.12344","article-title":"Ingenol mebutate gel for the treatment of Bowen\u2019s disease: a case report of three patients","volume":"29","author":"Salleras Redonnet","year":"2016","journal-title":"Dermatol. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2019.11.002_bb0555","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000447390","article-title":"Bowenoid actinic keratosis and Bowen\u2019s disease treated successfully with Ingenol Mebutate","volume":"232","author":"Mohanna","year":"2016","journal-title":"Dermatology"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2019.11.002_bb0560","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000447389","article-title":"Successful treatment of relapsing Bowen\u2019s disease with Ingenol Mebutate: the use of dermoscopy to monitor the therapeutic response","volume":"232","author":"Mainetti","year":"2016","journal-title":"Dermatology"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2019.11.002_bb0565","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000447391","article-title":"Ingenol Mebutate 150 mg as physician-directed treatment of Bowen\u2019s disease under occlusion","volume":"232","author":"Alkhalaf","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.addr.2019.11.002_bb0570","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1440-0960.1988.tb00383.x","article-title":"Home treatment of skin cancer and solar keratoses","volume":"29","author":"Green","year":"1988","journal-title":"Australas J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0575","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-03-2837","article-title":"Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death","volume":"64","author":"Ogbourne","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2019.11.002_bb0580","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/CCID.S28905","article-title":"New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel","volume":"5","author":"Berman","year":"2012","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0585","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1158\/0008-5472.CAN-09-4303","article-title":"The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2019.11.002_bb0590","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.4049\/jimmunol.177.11.8123","article-title":"Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with Ingenol-3-angelate","volume":"177","author":"Challacombe","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2019.11.002_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153975","article-title":"IL-1 contributes to the anti-cancer efficacy of Ingenol Mebutate","volume":"11","author":"Le","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2019.11.002_bb0600","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-0960.2008.00497.x","article-title":"PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study","volume":"50","author":"Siller","year":"2009","journal-title":"Australas J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0605","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","article-title":"Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis","volume":"60","author":"Anderson","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0610","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol Mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2019.11.002_bb0615","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2019.11.002_bb0620","doi-asserted-by":"crossref","first-page":"4381019","DOI":"10.1155\/2018\/4381019","article-title":"Efficacy of Ingenol Mebutate in the treatment of actinic Keratoses: a pre- and posttreatment dermoscopic comparative analysis","volume":"2018","author":"Carbotti","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2019.11.002_bb0625","doi-asserted-by":"crossref","first-page":"AB168","DOI":"10.1016\/j.jaad.2018.05.688","article-title":"Ingenol mebutate gel for the treatment of Bowen's disease","volume":"79","author":"Kim","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0630","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/1346-8138.14240","article-title":"Clinical experience of ingenol mebutate gel for the treatment of Bowen\u2019s disease","volume":"45","author":"Lee","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0635","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13555-014-0051-4","article-title":"Recurrent in situ melanoma successfully treated with ingenol mebutate","volume":"4","author":"Mansuy","year":"2014","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2019.11.002_bb0640","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000447393","article-title":"Ingenol Mebutate for Lentigo Maligna: a case report","volume":"232","author":"Gadaldi","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.addr.2019.11.002_bb0645","doi-asserted-by":"crossref","first-page":"e21051","DOI":"10.1200\/JCO.2019.37.15_suppl.e21051","article-title":"Ingenol mebutate to treat lentigo maligna of the head (face and scalp): a prospective and multicenter single-arm phase 2 trial","volume":"37","author":"Montaudi\u00e9","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2019.11.002_bb0650","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199912023412312","article-title":"Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma","volume":"341","author":"Peris","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2019.11.002_bb0655","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/14712598.2014.913564","article-title":"Sinecatechins (Polyphenon E) ointment for treatment of external genital warts and possible future indications","volume":"14","author":"Stockfleth","year":"2014","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2019.11.002_bb0660","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamadermatol.2017.2529","article-title":"Topical Sinecatechins, 10%, ointment for superficial basal cell carcinoma: a randomized clinical trial","volume":"153","author":"Kessels","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0665","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjd.15364","article-title":"A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma","volume":"177","author":"Gilbert","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.addr.2019.11.002_bb0670","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1039\/C5NP00153F","article-title":"I only have eye for ewe: the discovery of cyclopamine and development of hedgehog pathway-targeting drugs","volume":"33","author":"Chen","year":"2016","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.addr.2019.11.002_bb0675","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0304-3835(98)00081-0","article-title":"Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice","volume":"129","author":"Park","year":"1998","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2019.11.002_bb0680","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","article-title":"Therapeutic roles of curcumin: lessons learned from clinical trials","volume":"15","author":"Gupta","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2019.11.002_bb0685","first-page":"92","article-title":"Curcumin: a review of Its\u2019 effects on human health","volume":"6","author":"Hewlings","year":"2017","journal-title":"Foods (Basel, Switzerland)"},{"key":"10.1016\/j.addr.2019.11.002_bb0690","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The essential medicinal chemistry of curcumin","volume":"60","author":"Nelson","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2019.11.002_bb0695","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/030089168707300105","article-title":"Turmeric and curcumin as topical agents in cancer therapy","volume":"73","author":"Kuttan","year":"1987","journal-title":"Tumori"},{"key":"10.1016\/j.addr.2019.11.002_bb0700","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/(SICI)1097-4644(1997)27+<26::AID-JCB7>3.0.CO;2-3","article-title":"Inhibitory effects of curcumin on tumorigenesis in mice","volume":"27","author":"Huang","year":"1997","journal-title":"J. Cell. Biochem. Suppl."},{"key":"10.1016\/j.addr.2019.11.002_bb0705","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2012\/147863","article-title":"Topical curcumin-based cream is equivalent to dietary curcumin in a skin cancer model","volume":"2012","author":"Sonavane","year":"2012","journal-title":"J. Skin Cancer"},{"key":"10.1016\/j.addr.2019.11.002_bb0710","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1073\/pnas.182429899","article-title":"Topical applications of caffeine or (\u2212)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice","volume":"99","author":"Lu","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2019.11.002_bb0715","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3835(01)00718-2","article-title":"Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells","volume":"175","author":"Zuco","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2019.11.002_bb0720","first-page":"128","article-title":"Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study","volume":"7","author":"Huyke","year":"2009","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.addr.2019.11.002_bb0725","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/bjd.13342","article-title":"Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial","volume":"172","author":"Pflugfelder","year":"2015","journal-title":"Br. J. Dermatol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X19301930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X19301930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:48:27Z","timestamp":1759207707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X19301930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":145,"alternative-id":["S0169409X19301930"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2019.11.002","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical treatments for skin cancer","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}